Might dolutegravir be part of a functional cure for HIV? | Zendy

Mark A. Wainberg | Zendy; Ying-Shan Han | Zendy; Thibault Mésplède | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Might dolutegravir be part of a functional cure for HIV?

Author(s) -

Mark A. Wainberg,

Ying-Shan Han,

Thibault Mésplède

Publication year - 2016

Publication title -

canadian journal of microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.635

H-Index - 94

eISSN - 1480-3275

pISSN - 0008-4166

DOI - 10.1139/cjm-2015-0725

Subject(s) - elvitegravir , dolutegravir , raltegravir , integrase , human immunodeficiency virus (hiv) , drug resistance , integrase inhibitor , antiretroviral therapy , virology , antiretroviral agents , medicine , pharmacology , biology , genetics , viral load

Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research